Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Rev. bras. farmacogn ; 20(2): 240-245, Apr.-May 2010. ilus, graf, tab
Article in English | LILACS | ID: lil-550022

ABSTRACT

A total of twenty different extracts from six Brazilian Bromeliaceae species was screened for antioxidant activity by assessment of their capacity to scavenge the DPPH radical. In a general way, the polar rhizome extracts from Bromeliaceae representatives showed better antioxidant results than the extracts from leaves and fruits of the same species. The best results were found for the rhizome extracts of Vriesea procera (Mart. ex Schult.f.) Wittm. and Neoregelia cruenta (Graham) L.B. Sm. Crude methanol extract of Ananas bracteatus (Lindl.) Schult. & Schult. f. leaf had a significant antiradical activity among the leaves extracts assessed its purification afforded four metabolites: 2-O-feruloyl glyceride, 2-O-p-coumaroyl glyceride, 5,7,4'-trihydroxy-3,3',5'-trimethoxyflavone and 3-O-β-D-glucopyranosyl sitosterol.


Um total de vinte extratos de seis espécies de Bromeliaceae brasileiras foram avaliadas quanto a atividade antioxidante, usando-se o método colorimétrico de redução do radical DPPH. De maneira geral, os extratos polares dos rizomas das espécies de Bromeliaceae testadas revelaram melhor perfil antioxidante do que os extratos das folhas e dos frutos das mesmas espécies. Os melhores resultados foram encontrados para os rizomas de Vriesea procera (Mart. ex Schult.f.) Wittm. e Neoregelia cruenta (Graham) L.B. Sm. O extrato bruto metanólico das folhas de Ananas bracteatus (Lindl.) Schult. & Schult. f. apresentou uma atividade significativa, em relação aos extratos de folhas testados, e o processo de purificação desse extrato resultou na identificação de quatro metabólitos: ferulato de 2-glicerila, p-cumarato de 2-glicerila, 5,7,4'-triidroxi-3,3',5'-trimetoxiflavona e 3-O-β-D-glicopiranosil sitosterol.

2.
Mem. Inst. Oswaldo Cruz ; 100(supl.1): 161-165, Mar. 2005.
Article in English | LILACS | ID: lil-402193

ABSTRACT

It is presumed that drugs able to prevent bronchial spasm and/or inflammation may have therapeutic potential to control asthma symptoms. The local anaesthetic lidocaine has recently received increased attention as an alternative form of treatment for asthmatic patients. This paper reviews the major findings on the topic and summarizes the putative mechanisms underlying the airway effects of local anaesthetic agents. We think that lidocaine extends the spectrum of options in asthma therapy, probably by counteracting both spasmogenic and inflammatory stimuli in the bronchial airways. The possibility of development of new anti-asthma compounds based on the synthesis of lidocaine derivatives is also on the horizon.


Subject(s)
Humans , Anesthetics, Local/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Lidocaine/therapeutic use
3.
Mem. Inst. Oswaldo Cruz ; 92(supl.2): 37-43, Dec. 1997. tab, graf
Article in English | LILACS | ID: lil-202013

ABSTRACT

The eosinophilic response has been identified as a key alteration in the pathogenesis of asthma and other allergic diseases. A close-correlation between disease severity and eosinophilia, and the eosinophil ability to provide toxic and pro-inflammatory agents are the major elements supporting the interpretation that there is indeed a causal relationship between these phenomena. Nevertheless, controversy still persists since some studies have clearly demonstrated that eosinophil infiltration is not necessarily accompanied by tissue damage or hyperresponsiveness. In addition, there are some examples in the literature in which such alterations are not modified following abrogation of eosinophil influx. In this review it will be argued, based on a model of IgE-dependent pleuristy, that eosinophil infiltration can be associated with down-regulation of allergic inflammatory response. The potential mechanism by which eosinophils could be acting as a immunomodulatory cells in this particular system will also be assessed.


Subject(s)
Humans , Eosinophils/immunology , Hypersensitivity , Inflammation , Asthma , Prostaglandins
4.
Mem. Inst. Oswaldo Cruz ; 92(supl.2): 201-4, Dec. 1997. tab, graf
Article in English | LILACS | ID: lil-202033

ABSTRACT

In the present study, we have performed a comparative analysis of the effect of selective inhibitors of phosphodiesterase (PDE) type III, IV and V on eosinophil chemotaxis triggered by platelet activating factor (PAF) and leukotriene B4 (LTB4) in vitro. The effect of the analogues N6-2'-O-dibutyryladenosine 3':5' cyclic monophosphate (Bt2 cyclic AMP) and N2-2'-O-dibutyrylguanosine 3':5' cyclic monophosphate (Bt2 cyclic GMP) has also been determined. The eosinophils were obtained from the peritoneal cavity of naive Wistar rats and purified in discontinuous Percoll gradients to 85-95 per cent purity. We observed that pre-incubation of eosinophils with the PDE type IV inhibitor rolipram suppressed the chemotactic response triggered by PAF and LTB4 in association with an increase in the intracellular levels of cyclic AMP. In contrast, neither zaprinast (type V inhibitor) nor type III inhibitors milrinone and SK&F 94836 affected the eosinophil migration. Only at the highest concentration tested did the analogue Bt2 cyclic AMP suppress the eosinophil chemotaxis, under conditions where Bt2 cyclic GMP was ineffective. We have concluded that inhibition of PDE IV, but not PDE III or V, was able to block the eosinophil chemotaxis in vitro, suggesting that the suppresive activity of selective PDE IV inhibitors on tissue eosinophil accumulation may, at least, be partially dependent on their ability to directly inhibit the eosinophil migration.


Subject(s)
Animals , Rats , Chemotactic Factors, Eosinophil , In Vitro Techniques , Phosphodiesterase Inhibitors , Cell Movement/drug effects , Leukotriene B4 , Platelet Activating Factor
5.
Mem. Inst. Oswaldo Cruz ; 92(supl.2): 219-22, Dec. 1997. graf
Article in English | LILACS | ID: lil-202037

ABSTRACT

Previous studies have evidenced for the existence of interactive regulatory mechanisms between insulin and steroid hormones in different systems. In this study, we have investigated whether endogenous corticosteroids could be implicated in the hyporeactivity to antigen challenge observed in sensitized diabetic rats. Alloxinated rats showed a long-lasting increase in the blood glucose levels and a reduction in the number of pleural mast cells at 48 and 72 hr, but not at 24 hr after alloxan administration. In parallel, they also showed a significant elevation in the plasma levels of corticosterone together with an increase in the adrenal/body weight ratio. Antigen-evoked eosinophil accumulation appeared significantly reduced in rats pretreated with dexamethasone as weel as in those rendered diabetic 72 hr after alloxan. In the same way, naive animals treated with dexamethasone also responded with a significant decrease in the number of pleural mast cells. Interestingly, when sensitized diabetic rats were pretreated with the steroid antagonist RU 38486 a reversion of the reduction in the allergen-induced eosinophil accumulation was noted. We conclude that the down-regulation of the allergic inflammatory response in diabetic rats is close-related to reduction in mast cell numbers and over expression of endogenous corticosteroids.


Subject(s)
Humans , Rats , Adrenal Cortex Hormones , Pulmonary Eosinophilia/therapy , Alloxanum , Dexamethasone , Diabetes Mellitus , Hypersensitivity/therapy , Inflammation/therapy
6.
Ciênc. cult. (Säo Paulo) ; 42(7): 458-63, jul. 1990.
Article in English | LILACS | ID: lil-96124

ABSTRACT

PAF-aceter é um fosfolipídio que exerce um papel importante na reaçäo inflamatória aguda. No modelo experimental do edema da para de rato e pleurisia, a reaçäo induzida pelo PAF era acompanhada de hemoconcentraçäo, embora esses processos pareçam ser mediados por mecanismos distintos. Antagonistas específicos do PAF, como BN 52021 e WEB 2086, inibem 60% do edema induzido pelo PAF. Leucotrienos e mecanismos histaminérgicos envolvendo receptores H2 parecem participar no processo. A participaçäo do sistema adrenérgico e de metabólitos da ciclooxigenase é controversa. Infiltraçäo de leucócitos, observada após a injeçäo de PAF, e plaquetas näo säo necessárias para a formaçäo de edema. Auto-dessensibilizaçäo induzida pelo PAF pôde ser observada, sendo seletiva e dependente a interaçäo do PAF com receptores específicos em um processo de regulaçäo depressiva ("dow-regulation"). Nenhuma participaçäo deo PAF foi observada na reaçäo inflamatória induzida pela carregenina, contrariamente áquela provocada pelo zimosan, que é principalmente dependente do PAF-aceter


Subject(s)
Rats , Animals , Platelet Activating Factor/pharmacology , Inflammation/drug therapy , Carrageenan/pharmacology , Edema/chemically induced , Edema/drug therapy , Platelet Activating Factor/antagonists & inhibitors , Platelet Activating Factor/pharmacokinetics , Inflammation/chemically induced , Pleurisy/chemically induced , Pleurisy/drug therapy , Zymosan/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL